|
Jul 29
|
Novo Lifer Takes Job of Reviving Europe’s Weight-Loss Superstar
|
|
Jul 29
|
Novo's new CEO faces sceptical investors with Wegovy US sales in focus
|
|
Jul 29
|
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
|
|
Jul 29
|
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
|
|
Jul 29
|
Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.
|
|
Jul 29
|
Novo Nordisk cuts earning forecasts again, names new CEO
|
|
Jul 29
|
Novo Nordisk shares plummet over 20% on weight-loss drug sale slump
|
|
Jul 29
|
Novo Nordisk plunges as it cuts forecasts again and names new CEO
|
|
Jul 29
|
Instant View: Reaction to new Novo Nordisk CEO, profit warning
|
|
Jul 28
|
Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY)
|
|
Jul 28
|
Ireland's 'economic miracle' at risk from tariffs
|
|
Jul 28
|
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
|
|
Jul 28
|
This is the Most Dangerous Week for Investors in 20 Years
|
|
Jul 28
|
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
|
|
Jul 28
|
Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex
|
|
Jul 28
|
Morgan Stanley Remains Bullish on Eli Lilly (LLY)
|
|
Jul 28
|
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
|
|
Jul 27
|
The Patients Forced to Switch From Zepbound to Wegovy
|
|
Jul 27
|
Leerink Partners and Jefferies Issue Bullish Ratings on Eli Lilly and Company (LLY)
|
|
Jul 26
|
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
|